X
<

Eli Lilly’s 1Q17 Earnings Release Is Near: Expect Revenue Growth

PART:
1 2 3 4 5 6 7 8 9
Part 5
Eli Lilly’s 1Q17 Earnings Release Is Near: Expect Revenue Growth PART 5 OF 9

How Will Eli Lilly’s Alimta and Other Oncology Products Perform?

Oncology franchise

Eli Lilly and Company’s (LLY) human pharmaceutical segment includes its oncology franchise. Oncology contributes around 18.0% to Lilly’s total revenues. Key drugs in this segment include Alimta, Erbitux, and Cyramza. A new drug, Portrazza, was launched in US markets in December 2015.

How Will Eli Lilly’s Alimta and Other Oncology Products Perform?

Interested in LLY? Don't miss the next report.

Receive e-mail alerts for new research on LLY

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Alimta

Alimta, a chemotherapy drug used in the treatment of patients with advanced NSCLC (non-small cell lung cancer), is expected to report a fall in revenues for 1Q17. The fall is mainly due to competition from other products in US markets.

Erbitux

Erbitux is a drug used in the treatment of metastatic colorectal cancer and head and neck cancer. Lilly took back the commercialization rights for Erbitux in North America from Bristol-Myers Squibb (BMY) on October 1, 2015. So Erbitux revenues for 1Q17 will be reported by Lilly. That’s expected to be further supported by increased sales in international markets, resulting in growth for Erbitux revenues in 1Q17.

Some products similar to Erbitux are Roche’s (RHHBY) Avastin and Amgen’s (AMGN) Vectibix.

Other drugs in the oncology franchise

Other drugs in Lilly’s oncology franchise include Cyramza and Portrazza. Cyramza revenues are expected to rise in 1Q17 following a strong uptake in Japan as well as its launch in European markets. Portrazza, a new drug launched in December 2015, is expected to report revenue growth in 1Q17.

To divest the risk, you can consider ETFs such as the iShares US Pharmaceuticals (IHE), which holds 6.3% of its total assets in Eli Lilly, 5.5% in Bristol-Myers Squibb (BMY), 3.6% in Mylan (MYL), and 7.0% in Allergan (AGN).

X

Please select a profession that best describes you: